Inari Medical, Inc. (NASDAQ:NARI – Get Rating) Director Donald B. Milder sold 7,000 shares of the stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $80.25, for a total transaction of $561,750.00. Following the completion of the transaction, the director now directly owns 3,199,614 shares of the company's stock, valued at approximately $256,769,023.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Inari Medical Trading Down 5.6 %

Shares of NARI traded down $4.15 during mid-day trading on Friday, hitting $69.60. 3,961,657 shares of the company traded hands, compared to its average volume of 681,520. Inari Medical, Inc. has a one year low of $50.50 and a one year high of $100.00. The business has a 50-day moving average of $75.54 and a 200 day moving average of $75.87. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of -237.72 and a beta of 1.49.

Inari Medical (NASDAQ:NARI – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. Inari Medical had a negative net margin of 4.47% and a negative return on equity of 4.60%. The business had revenue of $92.74 million for the quarter, compared to analysts' expectations of $88.04 million. As a group, analysts anticipate that Inari Medical, Inc. will post -0.67 earnings per share for the current year.

Institutional Trading of Inari Medical

Wall Street Analyst Weigh In

NARI has been the subject of several recent research reports. Morgan Stanley dropped their price target on shares of Inari Medical from $108.00 to $93.00 and set an "overweight" rating for the company in a research report on Friday, July 15th. Piper Sandler initiated coverage on shares of Inari Medical in a research report on Tuesday, June 21st. They issued an "overweight" rating and a $100.00 price target for the company. Canaccord Genuity Group increased their price target on shares of Inari Medical from $92.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday. Canaccord Genuity Group increased their price target on shares of Inari Medical from $92.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday. Finally, BTIG Research dropped their price objective on shares of Inari Medical from $130.00 to $100.00 and set a "buy" rating for the company in a report on Friday, June 24th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.71.

Inari Medical Company Profile

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Stories

• Get a free copy of the StockNews.com research report on Inari Medical (NARI)
• 3 Banks Worth Considering For Q4
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• Is There a Cure for What is Ailing Teladoc Stock?
• MarketBeat: Week in Review 9/12 – 9/16
• No One Told These 3 Stocks It's a Down Week

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.